Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission.
Ruth StuckeyJuan Francisco López RodríguezMaría Teresa Gómez-CasaresPublished in: Current oncology reports (2022)
Cellular and molecular factors with a suggested role in TFR include immune factors and leukemic stem cell (LSC) persistence; the BCR::ABL1 transcript type, halving time, and BCR::ABL1 DNA and RNA positivity; as well as other molecular factors such as somatic mutations, RNA expression, and telomere length. Our review presents several biomarkers with predictive value for TFR but also highlights areas of unmet need. Future discontinuation guidelines will likely include biological factors for the personalization of TFR prediction. However, it will be important that such advances do not prevent more patients from making a TKI discontinuation attempt.
Keyphrases
- chronic myeloid leukemia
- tyrosine kinase
- stem cells
- end stage renal disease
- chronic kidney disease
- ejection fraction
- single molecule
- acute lymphoblastic leukemia
- newly diagnosed
- acute myeloid leukemia
- gene expression
- rheumatoid arthritis
- systemic lupus erythematosus
- epidermal growth factor receptor
- dna methylation
- clinical practice
- patient reported outcomes
- nucleic acid
- cell therapy
- copy number
- genome wide
- binding protein
- combination therapy
- circulating tumor cells